Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018503 | 0.88 | OPRD1 (0.47) | OPRD1KMT2AOPRK1PTGDR2S1PR5 | |
| SCHEMBL3019020 | 0.85 | HSD11B1 (0.40) | RORCS1PR5 | |
| SCHEMBL3022615 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL3026582 | 0.80 | TRPM8 (0.44) | — | |
| SCHEMBL3007280 | 0.78 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2 | |
| SCHEMBL3017767 | 0.77 | TP53 (0.39) | SMN1; SMN2 | |
| SCHEMBL4748618 | 0.76 | DRD2 (0.36) | — | |
| SCHEMBL3020628 | 0.76 | TRPM8 (0.44) | — | |
| SCHEMBL3025448 | 0.73 | ELOVL6 (0.43) | KMT2AS1PR5 | |
| SCHEMBL4694626 | 0.71 | PSEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | OPRD1 68/4885KMT2A 3054/4885OPRK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.